During Q3 2018 the big money sentiment increased to 1.15. That’s change of 0.19, from 2018Q2’s 0.96. 12 investors sold all, 50 reduced holdings as Ultragenyx Pharmaceutical Inc. ratio increased. 37 increased holdings while 34 funds acquired holdings. Funds hold 48.78 million shares thus 1.90% more from 2018Q2’s 47.88 million shares.
Rock Springs Capital Management Lp has 200,000 shs. Timpani Capital Llc invested in 0.71% or 32,235 shs. Jbf Incorporated invested 0.06% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). State Of Wisconsin Invest Board accumulated 48,800 shs. Clearbridge Invests Limited Liability Corp has invested 0.07% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Rothschild And Asset Us invested in 28,907 shs or 0.02% of the stock. Rhumbline Advisers invested in 42,520 shs or 0.01% of the stock. Tower Cap Limited Liability Com (Trc) holds 0% of its capital in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for 655 shs. Great West Life Assurance Can stated it has 5,344 shs. Sector Gamma As reported 14,939 shs. Natl Bank Of America De reported 50,579 shs. Moreover, Intll Sarl has 0.6% invested in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for 83,000 shs. The California-based Investors has invested 0.03% in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). Opus Point Partners Mngmt Ltd accumulated 6,134 shs or 1.12% of the stock. Moreover, Capital Rech Glob Investors has 0.13% invested in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) for 5.86M shs.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) increased significantly to $63.04. Barchart.com reported the move on Feb, 25. The company has $3.19B MC. $287.01M more could be NASDAQ:RARE valuation at $68.71 share price.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Ratings Coverage

Total analysts of 10 have positions in Ultragenyx Pharmaceutical (NASDAQ:RARE) as follows: 6 rated it a “Buy”, 0 with “Sell” and 4 with “Hold”. The positive are 60%. Since August 30, 2018 according to StockzIntelligence Inc Ultragenyx Pharmaceutical has 15 analyst reports. The stock rating was maintained by Credit Suisse with “Neutral” on Monday, October 29. On Monday, October 29 the rating was maintained by Wedbush with “Outperform”. On Monday, October 29 the firm has “Buy” rating by SunTrust given. On Tuesday, February 19 the firm has “Buy” rating by Piper Jaffray given. On Tuesday, September 11 the firm has “Buy” rating by Bank of America given. On Monday, October 29 the stock of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) earned “Sell” rating by Citigroup. On Thursday, February 21 the company was maintained by Jefferies. On Thursday, August 30 the rating was maintained by Wedbush with “Outperform”. On Tuesday, February 19 the stock of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) earned “Buy” rating by Barclays Capital. On Monday, September 10 Morgan Stanley reinitiated the shares of RARE in report with “Equal-Weight” rating.

For more Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) news posted briefly go to: Nasdaq.com, Nasdaq.com, Nasdaq.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “U.S. returns to Bitfinex exchange fraction of bitcoin stolen in 2016 heist – Nasdaq” posted on February 25, 2019, “Members of the Military—Save to Retire – Nasdaq” on February 24, 2019, “Verizon’s Green bond debut opens up new funding channel – Nasdaq” with a publish date: February 08, 2019, “The Zacks Analyst Blog Highlights: Merck, Design, Roche and AbbVie – Nasdaq” and the last “Cameras spot Kenya’s rare black panther – Nasdaq” with publication date: February 14, 2019.

Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States.The firm is worth $3.19 billion. The firm is developing various biologics product candidates, including KRN23, a human monoclonal antibody that in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia.Last it reported negative earnings. The Company’s biologics product candidates also comprise recombinant human beta -glucuronidase , an enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy, which is in preclinical development for galactosialidosis.